Dr. Salloway Director of Neurology and The Memory and Aging Program (MAP) at Butler Hospital in Providence, Rhode Island and Professor of Clinical Neurosciences and Psychiatry at Brown Medical School. He received his M.D. from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University. Dr. Salloway has published more than 140 scientific articles, book chapters, and abstracts and has edited 3 books. His research focuses on a) clinical trials for prevention and treatment of Alzheimer's disease, mild cognitive impairment, and vascular dementia b) studies of genetic and sporadic forms of microvascular brain disease and c) the development of imaging biomarkers to study conversion to dementia. Dr. Salloway is an expert on amnestic mild cognitive impairment (MCI) and vascular cognitive impairment, transitional states at high risk for conversion to Alzheimer’s disease and vascular dementia. He recently published the first controlled clinical trial of a cholinesterase inhibitor for the treatment of MCI. Under his direction the Butler Memory and Aging Program has become a national referral center for the study of CADASIL, an autosomal dominant disorder causing small artery degeneration in the brain. CADASIL provides an excellent model for studying microvascular brain disease and Dr. Salloway is currently helping to design the first controlled trial for CADASIL. He is collaborating with Dr. Stopa, professor of pathology, and Dr. Fallon, professor of neuroscience, on an NIH-funded project studying genetic models of human dementia. He is also using MRI diffusion tensor imaging to better understand the neural networks involved in mediating frontal behavior and executive function in collaboration with Dr. Laidlaw from computer science, and Dr. Malloy, from psychiatry.

Dr. Salloway is the Past President of the American Neuropsychiatric Association and has been elected a member of the American Neurological Association. He serves on national and international committees to develop diagnostic criteria and new treatments for dementia. He is a scientific reviewer for the National Institutes of Health, the Harvard Center for Neurodegeneration and Repair and for more than 25 journals, universities, and research foundations. Dr. Salloway is the Director of the Brown Combined Residency in Neurology and Psychiatry, co-Principal Investigator of the NIA-funded Brown Dementia Research Fellowship Program, Director of the Brown Neuropsychiatry Track in the Psychiatry Residency and Director of the first year medical student course, The Human Brain and Behavior. Dr. Salloway has made more than 200 invited lectures and research presentations on dementia and neuropsychiatric disorders at regional, national and international meetings.